Patients with severe aortic stenosis who undergo TAVR enjoy a minor but significant sustained health benefit that isn’t mirrored in patients who opt for surgical AVR, according to research reported at TCT 2019 in San Francisco.

Sleeping less than six hours a night could significantly raise a person’s risk of cancer or early death if they’re middle-aged and have high blood pressure, type 2 diabetes, heart disease or a history of stroke, according to work published in the Journal of the American Heart Association.

An updated meta-analysis centered around the role marine omega-3 supplementation in CVD prevention suggests there may be a use for fish oil in cardiovascular medicine after all.

The FDA approved canagliflozin Sept. 30 to reduce the risk of end-stage kidney disease, worsening kidney function, CV death and hospitalization for heart failure in adults with type 2 diabetes and diabetic nephropathy.

Vermont senator and presidential hopeful Bernie Sanders was hospitalized Tuesday for an artery blockage that required two stents, the New York Times reports.

A simplified cardiac risk score can identify plaque buildup and silent brain infarctions that could predict a serious stroke, acting as a red flag for patients without a history of CVD or other vascular problems.

A panel of 14 international scientists published a nutritional guideline in the Annals of Internal Medicine this month suggesting adults continue consuming both red meat and processed meats, basing the recommendation on a mega-review that found few adverse health effects with either product.

An economic analysis of COAPT data suggests edge-to-edge TMVR with the MitraClip device is a more affordable long-term treatment option than guideline-directed medical therapy alone for patients with severe secondary MR—but the steep cost of an index TMVR procedure might eclipse that benefit.

The higher the dosage of cholesterol-lowering statins, the greater a patient’s risk of developing osteoporosis, according to work published in the Annals of Rheumatic Diseases.

CVS Pharmacy announced Sept. 28 it would be suspending the sales of all Zantac-brand and CVS Health-brand ranitidine products until further notice, pending the results of an FDA investigation.